KLOW
$149.99
Research-Grade Compound · RUO
KLOW Research Blend 80mg (GHK-Cu · KPV · BPC-157 · TB-500)
Pre-blended 80mg four-peptide dermal and connective tissue research panel — GHK-Cu 50mg, KPV 10mg, BPC-157 10mg and TB-500 10mg — studied for extracellular matrix remodeling, melanocortin receptor signaling, actin cytoskeletal dynamics, and growth factor pathway biology in coordinated in-vitro multi-analyte assay systems
$149.99
80 mgUSD · Research GradeGHK-Cu 50mg · KPV 10mg · BPC-157 10mg · TB-500 10mg
In stock — ships same or next business day from the United States
Lyophilized, filled and sealed in our U.S. facility from globally sourced peptide. Independently third-party tested, with batch-specific COAs on file.
Purity Guarantee
If any compound falls short of ≥99% purity on its COA, contact us and we'll make it right.
Add $200.00 more for free shipping. Keep Shopping
⚗ Research Use Only. Not for human consumption.
Scientific Context
Research Applications
- 01
Dermatological researchers investigating coordinated four-peptide effects on collagen biosynthesis, elastin gene expression, and extracellular matrix remodeling in human fibroblast and keratinocyte co-culture models
- 02
Cell biology laboratories examining compound synergy across melanocortin receptor (MC1R/MC3R) signaling, actin cytoskeletal dynamics, and growth factor pathway engagement within a single in-vitro system
- 03
Scientists studying copper-dependent enzymatic activity (GHK-Cu), melanocortin-mediated NF-κB pathway modulation (KPV), actin-mediated cellular migration biology (TB-500), and fibroblast proliferation signaling (BPC-157) as a coordinated multi-pathway in-vitro research panel
Observed Mechanisms
In-Vitro Activity Profile
GHK-Cu 50mg: Copper-Mediated Matrix Remodeling
The tripeptide-copper complex GHK-Cu has been studied in vitro for copper ion transport into dermal fibroblasts, engaging copper-dependent enzymatic pathways and upregulating collagen I, III, and elastin gene expression — providing the extracellular matrix remodeling arm of the panel.
KPV 10mg: Melanocortin Receptor & NF-κB Pathway
KPV, the C-terminal tripeptide of α-MSH, has been studied for binding affinity at MC1R and MC3R subtypes with downstream effects on cAMP signaling and NF-κB pathway modulation, contributing the melanocortin receptor and anti-inflammatory signaling dimension to the combined panel.
TB-500 10mg: Actin Dynamics & Cellular Migration
TB-500 binds monomeric G-actin through its LKKTET motif, modulating cytoskeletal reorganization and cellular motility in scratch assay models — contributing the cellular migration and angiogenic signaling dimension of the combined panel.
BPC-157 10mg: Growth Factor & Fibroblast Activity
BPC-157 contributes growth factor receptor pathway engagement and fibroblast proliferation signaling to the panel, with preclinical studies documenting associations with epithelial cell proliferation markers and collagen synthesis rate changes in connective tissue culture systems.
Related Compounds
Frequently Researched Together
KLOW is a single pre-blended 80mg vial combining GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg) and TB-500 (10mg) — extending the three-peptide GLOW dermal panel with KPV, the C-terminal alpha-MSH tripeptide, which adds melanocortin receptor and NF-kB pathway coverage to the extracellular matrix remodeling (GHK-Cu), actin cytoskeletal (TB-500) and growth factor pathway (BPC-157) arms.
Common Questions